Causes of delay in referral of patients with phenylketonuria to a specialized reference centre in Mexico

M Vela-Amieva1, I Ibarra-González, C Fernández-Lainez

  • 1Laboratorio de Errores Innatos del Metabolismo y Tamiz, Instituto Nacional de Pediatria, Secretaria de Salud, Mexico. dravelaamieva@yahoo.com

Insights

Late referral of phenylketonuria (PKU) patients in Mexico is primarily due to the absence of newborn screening (NBS) for PKU. Improving NBS program function is crucial for timely diagnosis and treatment.

Area of Science:

  • Medical Genetics
  • Pediatrics
  • Public Health

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring early detection and management.
  • Delayed diagnosis of PKU can lead to severe neurological complications.
  • Effective newborn screening (NBS) programs are vital for identifying infants with PKU.

Purpose of the Study:

  • To identify reasons for delayed patient referrals to a reference center for phenylketonuria (PKU).
  • To characterize the clinical presentation of PKU patients with delayed diagnosis.
  • To evaluate the effectiveness of the newborn screening (NBS) program in Mexico for PKU.

Main Methods:

  • Retrospective analysis of 57 PKU patient files over 18 years at the National Institute of Pediatrics, Mexico City.
  • Patients categorized into early (Group I, <1 month) and late (Group II, >30 days) referral groups.
  • Documentation of time delays and specific causes for late referrals.

Main Results:

  • Only 10 out of 57 patients were referred within the first month of life (Group I).
  • 47 patients (Group II) were referred late, with causes including lack of routine PKU testing, sampling issues, and administrative failures.
  • Absence of PKU testing in the NBS program was a significant factor in late referrals.

Conclusions:

  • The primary barrier to timely PKU diagnosis in Mexico is the lack of integrated PKU testing within the NBS program.
  • Challenges in NBS program expansion and function in Mexico contribute to delayed patient identification.
  • Enhancing the NBS system with PKU testing and quality indicators is essential for prompt PKU management.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...